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A retrospective observational study to review the safety and efficacy of rFVIIa in persistent hemorrhage in post
cardiac surgical patients.
Methods: Patients who had bleeding of 3 ml/kg/h or more for 2 consecutive hours after cardiac surgery were
arranged into two groups; control group, who received conventional treatment and rFVIIa group, who received con-
ventional treatment and rFVIIa.
Results: There was no significant difference in demographic and surgical characteristics of both groups. The chest
tube output significantly decreased in the rFVIIa group compared to the other group 4 hours after admission {1.4
(IQR: 1–2.2) ml/kg/h vs 3.9 (IQR: 3.1–5.6) ml/kg/h; p = 0.004} and continues to be significant till 9 hours after CSICU
admission {0.6 (IQR: 0.4–1.1) ml/kg/h vs 1.9 (IQR: 1.2–2.2) ml/kg/h; p = 0.04}. The median number of blood products
units transfused to rFVIIa group was significantly lower compared to control group in the period from 3–12 hours
after CSICU admission. 13 (5.5%) patients in rFVIIa group had Thromboembolic adverse events (TAE) compared
to 7 (2.4%) patients in other group p = 0.27. 8 patients in the rFVIIa group needed reexploration compared to 19
patients in the other group, p = 0.01. No significant difference was noticed between the 2 groups regarding: new
onset renal failure, median number of mechanical ventilator days, pneumonia, mediastinitis, ICU and hospital
lengths of stay, survival at 30 days and at discharge.
Conclusion: In this analysis, rFVIIa succefully reduced the chest tube bleeding and blood products transfused
during severe post cardiac surgical bleeding. However, safety of rFVIIa remains unclear. Prospective controlled tri-
als are still needed to confirm the role of rFVIIa.
 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Abbreviations
rFVIIa recombinant activated factor VII
CSICU Cardiac Surgical Intensive Care Unit
TAE Thromboembolic Adverse Events
CVA Cerebrovascular accidents
MI Myocardial infarction
PE Pulmonary embolism
DVT Deep venous thrombosis
ml/kg/h milliliter/ kilogram/hour
IQR Interquartile range
aPTT activate partial thromboplastin time
ACT activated Clotting time
INR international normalized ratio
gm/l gram/Liter
mcg/kg microgram/ kilogram
CPB cardiopulmonary bypass
FFP fresh frozen plasma
Cryo cryoprecipitate
ICU intensive care unit
35.5 C 35.5 degree celsius
mg/dl milligram/deciliter
RBCs red blood corpuscles
TAFI thrombin activation fibrinolysis inhibitor
PT pro-thrombin time
RCT Randomized Controlled Studies
FEIBA Factor Eight Inhibitor Bypass Activity
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UNCONTROLLED BLEEDING POSTCARDIAC SURGERYIntroduction
Despite improvements in surgical skills andstrategies, bleeding remains a problem in
cardiac surgery. Bleeding is also a significant
cause of morbidity and mortality, prolonged hos-
pital stay, and increased cost [1,2]. Increased risk
of postoperative complications as well as reduced
short- and long-term survival is associated with
the transfusion of red cells that have been stored
for >2 weeks in patients undergoing cardiac sur-
gery [3]. Other reports argue that for patients
undergoing cardiac surgery, bleeding contributes
to mortality through mechanisms unrelated to
blood transfusion [4]. Efforts to minimize the use
of limited resources such as blood products are
essential and the most obvious and probably the
most effective strategy is to improve surgical tech-
niques and hemostatic management.
Recombinant activated factor VII (rFVIIa) is a
potent prohemostatic agent currently approved
for bleeding in patients with hemophilia or other
congenital hemostasis and coagulation defects.
Over the past years, the estimated number of
patients treated with rFVIIa has grown rapidly,
mainly for off-label indications, including exces-
sive bleeding after trauma and cardiac operations
[5–10].
The rFVIIa promotes hemostasis by enhancing
the generation of thrombin on platelets. rFVII
complexes with all available tissue factor to acti-
vate factor X directly and induce thrombin gener-
ation. This results in the formation of a tight and
stable fibrin plug that is resistant to premature fib-
rinolysis [11].
The aim of our work is to present our experience
of the use of rFVIIa in treating intractable hemor-
rhage postcardiac surgery in adult patients with
respect to its efficacy and safety.Materials and methods
The study was conducted in the Cardiac Surgi-
cal Intensive Care Unit (CSICU), King Faisal Heart
Center, King Faisal Specialist Hospital and
Research Center, Riyadh, Saudi Arabia.
Patients
Retrospectively, the medical charts of all adult
patients (n = 4856) who had cardiac surgery in
the period between February 2004 and December
2013 were screened for the occurrence of postop-
erative bleeding in the intensive care unit (ICU).
Patients who were younger than 18 years, thosewho had a primary coagulation defect, pregnant
women, those who received rFVIIa in the operat-
ing room, those having surgery for the correction
of congenital heart diseases, requiring a mechani-
cal circulatory support device, or extracorporeal
membrane oxygenation in the operating room
were excluded (n = 42). All patients who had chest
tube bleeding of P3 mL/kg/h for P2 consecutive
hours postadmission to CSICU from the operating
room (n = 441) were included in the study and
arranged in two groups: control group [those
who received conventional treatment; Fig. 1 boxes
2, 4, and 6 (n = 207)]; and the rFVIIa group [those
who received conventional treatment and rFVIIa;
Fig. 1 boxes 2, 4, 6, and 7 (n = 234)].
The study protocol was approved by King Faisal
Research Center and Medical ethics committee.
Being a retrospective chart review study, consent
was waived by the ethical committee.
The patients’ demographics, preoperative
comorbidities, preoperative anticoagulation, pri-
ority of surgery, type of surgery, cardiopulmonary
bypass time (CPB), aortic cross clamp time, and
surgical re-exploration were collected. The Euro-
pean System for Cardiac Operative Risk Evalua-
tion II score system was used to assess the
severity for each patient [12].
Coagulation parameters (international normal-
ized ratio, activated partial thromboplastin time,
activated clotting time, and fibrinogen levels)
and platelets count were measured on admission
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Bleeding ≥ 3 ml/kg/h in the first hour 
1-Exclusion of surgical bleeding that needs re-exploration
2-correction of coagulation parameters with transfusion*
- Platelets transfusion if < 100.000/ml
- FFP transfusion if INR >1.5
- Cryprecipetate transfusion if Fibrinogen <200 mg/dl
- PRBC's transfusion if Hb < 7 gm/l
3-correction of ACT with protamine if > 140
4-correction of patient core temperature to >35.5ºc
5-correction of pH to >7.2
6-correction of ionizied Calcium to >1.1 mmol/l
Persistent bleeding ≥ 3 ml/kg/h in the second hour
1- Exclusion of surgical bleeding that needs re-exploration
2- DDAVP 20 mcg single IV dose
3- tranxemic acid 1000 mg IV dose and can be repeated q 6 hours if needed
4- Transfusion of blood &/or blood products according to coagulation 
parameters results* and to achieve target values (box 1)
5- Another dose of protamine if ACT is >140
6- correction of patient core temperature to >35.5ºc
7- correction of pH to >7.2
8- correction of ionizied Calcium to >1.1 mmol/l
Persistent bleeding ≥ 3 ml/kg/h in third hour
1- Exclusion of surgical causes that needs re-exploration
2- Transfusion of blood &/or blood products according to coagulation 
parameters results* and to achieve target values (box 1)
3- Another dose of protamine if ACT is >140
4- correction of patient core temperature to >35.5ºc
5- correction of pH to >7.2
6- correction of ionizied Calcium to >1.1 mmol/l
Persistent bleeding ≥ 3 ml/kg/h
Surgical re-exploration
ICU and surgical team joint discussion 
for rFVIIa 90 (40-120) mcg/kg)
(13)
(13)
(13)
Figure 1. Management protocol for bleeding postoperative patients in Cardiac Surgical Intensive Care Unit. aTransfusion of blood products
usually involved two to four units of platelets, two to four units of cryoprecipitate, one to two units of fresh frozen plasma, and one unit of packed
red blood cells for each 1 g of Hb <7 g/L at a time. ACT = activated clotting time; FFP = fresh frozen plasma; ICU = intensive care unit;
INR = International Normalized Ratio; IV = intravenous; PRBC = packed red blood cells; rFVIIa = recombinant factor VIIa.
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bleeding, then once daily and upon physician
request.
The primary end points of this workwere to com-
pare both groups regarding: (1) the efficacy defined
as: (a) the amount of bleeding from chest tube and
(b) the amount of blood products transfused; and
(2) the safety defined as incidence of thromboem-
bolic adverse events (TAE) [cerebrovascular
accidents (CVA), myocardial infarction (MI),pulmonary embolism (PE), deep venous thrombo-
sis, or arterial thrombosis]. Screening for TAE was
performed by physical examination. If a TAE was
suspected, color duplex sonography, trans-
esophageal echocardiography, computed tomog-
raphy scan, and laboratory tests were performed
to confirm the diagnosis.
The secondary endpoints were to compare the
two groups in regard to: (1) coagulation parame-
ters; (2) the need of surgical re-exploration; (3)
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UNCONTROLLED BLEEDING POSTCARDIAC SURGERYincidence of acute renal impairment defined as
increase of serum creatinine to >2 mg/dL or dou-
bling the most recent preoperative creatinine level
or a new requirement for dialysis postoperatively;
(4) new incidence of pneumonia diagnosed if the
patient had a new, persistent, or progressive lung
infiltrate on chest radiograph and if at least two of
the following criteria were present: temperature
P38 C, leukocytosis >12,000 cells/lL or leukope-
nia <3000 cells/lL, or purulent endotracheal
secretions with a gram stain showing >25 neu-
trophils and <10 epithelial cells per field; (5) medi-
astinitis defined as a superficial or deep infection
of the sternotomy wound with positive findings
on cultures obtained from the wound; (6) days
on mechanical ventilation; (7) CSICU and hospital
length of stay; and (8) survival at 30 days postop-
eratively and at discharge.Management of postoperative bleeding in CSICU
and use of rFVIIa
Fig. 1 shows the protocol for the management of
postoperative bleeding in our CSICU. Exclusion of
surgical causes of bleeding that required re-
exploration (cardiac tamponade, mediastinal
hematoma, or large hemothorax) was done
through clinical examination, hemodynamic mon-
itoring, and radiographic tools including chestTable 1. Demographic and surgical data of study patients.
Control
Age (y) 58 (21–78)
Weight 79 (48–102)
Male 133 (64.3)
Euro-score 7 (5–17)
Preoperative comorbidity
Diabetes 53 (25.6)
Creatinine >1.4 mg/dL 68 (32.8)
LVEF <40% 39 (18.8)
Previous MI 44 (21.2)
Previous CVA 9 (4.3)
Pulmonary embolism 0 (0 %)
Emergency surgery 33 (15.9)
Redo surgery 89 (42.9)
Preop anticoagulant 58 (28)
Preop antiplatelet 123 (59.4)
Type of surgery
Single valve 41 (19.8)
Multiple valves 63 (30.4)
CABG 48 (23.1)
CABG with valve(s) 39 (18.8)
Aortic surgery 11 (5.3)
Heart transplant 5 (2.4)
CPB time (min)a 127 (82–163)
Cross clamp time (min)a 92 (64–137)
Circulatory arrest time (min)a 19 (11–28)
Data are presented as n (%) or median (range). (min)a minute, (y) years.
CABG = coronary artery bypass grafting; CPB = cardiopulmonary bypass; CV
MI = myocardial infarction; Preop = preoperation.X-ray and bedside echocardiography, together
with the consultation of the attending cardiac sur-
geon [13]. The decision to administer rFVIIa was
made after a discussion between the ICU and sur-
gical teams regarding options for further treat-
ments, the risks associated with rFVIIa or re-
exploration, and hemodynamic state of the
patient, according to the protocol in Fig. 1. The
median rFVIIa dose used in our CSICU was 90
(interquartile range 40–120) mg/kg.
Statistical analysis
Summary statistics were presented as medians
with ranges. Categorical variables are presented
as counts and percentages. Group comparisons
were done using Fisher’s exact test for categorical
variables and the Mann–Whitney U test for con-
tinuous variables. A p value 60.05 was considered
significant in all tests. SPSS version 17 (SPSS Inc.,
Chicago, IL, USA) software was used to analyze
the data.Results
Demographic data
The medical records of 4856 patients who had
cardiac surgery done in the period from February
2004 to December 2013 were reviewed. FourrFVIIa p
60 (24– 73) 0.09
81 (46–113) 0.1
146 (62.4) 0.69
8.5 (4–19) 0.21
64 (27.3) 0.74
71 (30.3) 0.61
51 (21.8) 0.48
43 (18.3) 0.47
18 (7.6) 0.17
2 (0.9) 0.5
42 (17.9) 0.61
113 (48.3) 0.3
73 (31.1) 0.6
131 (56) 0.5
43 (18.4) 0.79
81 (34.6) 0.36
40 (17.1) 0.15
36 (15.3) 0.37
20 (8.5) 0.2
14 (6) 0.1
129 (76–181) 0.2
98 (59–141) 0.18
23 (14–34) 0.2
A = cerebral vascular accident; LVEF = left ventricular ejection fraction;
Table 2. Chest tube output in both treatment groups in the
Cardiac Surgical Intensive Care Unit.
Time (h) Control (mL/kg/h) rFVIIa (mL/kg/h) p
0–1a 4.3 (3.1–6.9) 5.1 (3.6–7.4) 0.1
1–2 4.6 (3.8–7.1) 4.5 (3.5–7.9) 0.5
2–3 4.2 (3.3–6.8) 3.6 (2.9 –7.1) 0.09
3–4 3.9 (3.1–5.6) 1.4 (1.0– 2.2) 0.004
4–5 3.4 (2.8–4.2) 1.3 (0.7–1.8) 0.009
5–6 2.8 (2.1–3.4) 1.0 (0.5–1.3) 0.03
6–7 2.5 (1.6–3.3) 0.8 (0.5–1.1) 0.03
7–8 1.9 (1.4–2.9) 0.8 (0.6–1.0) 0.05
8–9 1.9 (1.2–2.2) 0.6 (0.4–1.1) 0.04
9–12 1.1 (0.7–1.6) 0.3 (0.5–0.9) 0.08
Data are presented as median (range).
a 0 hour is on admission.
Table 3. Blood products requirements of the treatment groups in
the first 24 hours after admission to Cardiac Surgical Intensive
Care Unit.
Conrtol (units) rFVIIa (units) p
FFP 8 (4–11) 3 (2–6) 0.006
Platelets 11 (5–17) 4 (2–8) 0.009
Cryoprecipitate 8 (4–13) 2 (0–4) <0.001
PRBCs 6 (2–9) 2 (1–5) 0.01
Data are presented as median (range).
FFP = fresh frozen plasma; PRBCs = packed red blood corpuscles.
A 
C 
* 
* 
0 
1 
2 
3 
4 
5 
In OR 0–
– – –
– –3 h 3 6 h 6 12 h
FFP
Control
Control
* 
* 
0 
2 
4 
6 
8 
In OR 0 3 h 3 6 h 6 12 h
Cryo
rFVIIa
rFVIIa
Figure 2. Median units of blood products requirements of the two groups
(Cyro); (D) packed red blood cells (PRBC). ⁄p < 0.05. 0–3 hours = first 3
recombinant factor VIIa administration); 3–6 hours = after admission to
recombinant factor VIIa by this time); Group 1 = conventional treatme
disconnection of cardiopulmonary bypass until admission to Cardiac Sur
FU
LL LEN
G
TH
 A
RTIC
LE
226 HABIB ET AL
UNCONTROLLED BLEEDING POSTCARDIAC SURGERY
J Saudi Heart Assoc
2016;28:222–231hundred and eighty-three patients (9.9%) were
identified as having postoperative bleeding in
CSICU. Eighteen patients were excluded due to
receiving rFVIIa in the operating room, five for
having corrective surgery for congenital heart dis-
ease, and 19 for being assisted with mechanical
circulatory support. Two hundred and seven
patients were included in the control group
(received conventional treatment) and 234
patients were included in the rFVIIa group
(received rFVIIa in addition to conventional treat-
ment). There was no statistical significant differ-
ence in demographic and surgical characteristics
of both groups (Table 1).
Primary endpoints
The median time from leaving the operating
room until starting the rFVIIa was 187 (143–213)
minutes. The chest tube output was high in both
groups in the first 2 hours after admission to
CSICU, and then it showed a significant drop in
the rFVIIa group starting from 4 hours through
9 hours after admission compared with the control
group (Table 2). The median number of blood pro-
duct units used in the first 24 hours after admis-
sion to CSICU was statistically significant lowerB
D 
– – –
– – –
Control
Control
* 
* 
0 
2 
4 
6 
8 
In OR 0 3 h 3 6 h 6 12 h
PLT
* 
0 
1 
2 
3 
4 
In OR 0 3 h 3 6 h 6 12 h
PRBCs
rFVIIa
rFVIIa
. (A) Fresh frozen platelets (FFP); platelets (PLT); (C) cryoprecipitate
hours after Cardiac Surgical Intensive Care Unit admission (before
Cardiac Surgical Intensive Care Unit (all patients had received
nt group; Group 2 = recombinant factor VIIa group; In OR = after
gical Intensive Care Unit; OR = operating room.
Table 4. Blood products requirements of both groups after the
CPB and before admission to Cardiac Surgical Intensive Care
Unit.
In OR p
Conrtol (units) rFVIIa (units)
FFP 4 (2–7) 4 (3–6) 0.8
Platelets 6 (3–12) 5 (2–9) 0.6
Cryoprecipitate 2 (0–6) 3 (2–8) 0.1
PRBCs 3 (1–5) 2 (1–6) 0.8
Data are presented as median (range).
FFP = fresh frozen plasma; OR = operating room; PRBCs = packed red
blood corpuscles.
Table 5. Blood products requirements of both groups during the
first 3 hours after admission to Cardiac Surgical Intensive Care
Unit.
0–3 h p
Control (units) rFVIIa (units)
FFP 4 (2–5) 4 (2–6) 0.9
Platelets 5 (2–10) 4 (2–7) 0.7
Cryoprecipitate 4 (0–6) 4 (2–4) 0.1
PRBCs 2 (2–3) 2(1–4) 0.5
Data are presented as median (range).
FFP = fresh frozen plasma; PRBCs = packed red blood corpuscles.
Table 6. Blood products requirements of both groups from 3
hours to 6 hours after admission to Cardiac Surgical Intensive
Care Unit.
3–6 h p
Control (units) rFVIIa (units)
FFP 4 (1–6) 1 (0–1) 0.03
Platelets 6 (4–15) 0 (0–2) 0.001
Cryoprecipitate 6 (2–13) 0 (0–2) 0.008
PRBCs 2 (2–5) 1 (0–1) 0.04
Data are presented as median (range).
FFP = fresh frozen plasma; PRBCs = packed red blood corpuscles.
Table 7. Blood products requirements of both groups from
6 hours to 12 hours after admission to Cardiac Surgical
Intensive Care Unit.
6–12 h p
Control (units) rFVIIa (units)
FFP 3 (1–5) 0 (0–2) 0.009
Platelets 4 (0–4) 0 0.003
Cryoprecipitate 2 (0–8) 0 0.04
PRBCs 1 (0–2) 0 (0–1) 0.5
Data are presented as median (range).
FFP = fresh frozen plasma; PRBCs = packed red blood corpuscles.
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UNCONTROLLED BLEEDING POSTCARDIAC SURGERYin the rFVIIa group compared with the control
group (Table 3). Further analysis of the blood
products transfused showed no significant
difference between the two groups during the
operating room, after discontinuation of CBP,
and before transfer to CSICU (Table 4), or during
the first 3 hours after admission to CSICU
(Table 5). However, there were significant
differences between the groups during the peri-
ods from 3 hours to 12 hours after CSICU admis-
sion (Tables 6 and 7; Fig. 2).
A total of 20 patients (4.5%) of all patients had
thromboembolic complications. Seven (2.4%)
patients in conventional treatment group (5 CVA
and 2 MI) compared with 13 (5.5%) patients in
the rFVIIa group (7 CVA, 5 MI, and 1 PE), p = 0.27.Table 8. Coagulation parameters of the treatment groups on admiss
On admission
Control (s) rFVIIa (s)
aPTT 50.3 (34.1–67.5) 50.8 (35.6–71.7)
PT 18.7 (12.7–24.4) 19.4 (11.5–26.3)
ACT 156 (142–174) 162 (134–186)
INR 1.52 (0.87–2) 1.49 (0.73–2.1)
Fibrinogen (mg/L) 234 (174–279) 226 (188–261)
Platelet ( 109) 101 (54–210) 96 (46–198)
Data are presented as median (range). (s) seconds.
ACT = activated clotting time; aPTT = activated partial thromboplastin time;
a Four hours after admission to Cardiac Surgical Intensive Care Unit.Secondary endpoints
There were no statistical significant differences
of the coagulation parameters between the two
treatment groups on admission. However, the
activated partial thromboplastin time, prothrom-
bin time, activated clotting time, and international
normalized ratio became statistically significant
lower in the rFVIIa group 4 hours after admission
when compared with the control group (Table 8).
Eight patients in the rFVIIa group needed re-
exploration compared with 19 patients in the con-
ventional treatment group, p = 0.011. Five patients
of both groups had aortic surgery, 12 had small
arterial bleeder, one had injury at the CPB can-
nula site, and no specific cause of bleeding was
found in nine patients. The number of mechanicalion to Cardiac Surgical Intensive Care Unit and 4 hours later.
p Post-treatmenta p
Control (s) rFVIIa (s)
0.58 48.2 (31.1–66.5) 43.8 (27.6–56.3) 0.03
0.72 16.5 (10.8–20.7) 11.3 (10.3–14.1) 0.01
0.66 128.9 (113.2–134.7) 119.2 (109.8–127.3) 0.03
0.54 1.34 (0.67–1.8) 1.26 (0.92–1.56) 0.05
0.81 257 (189–274) 251 (201–293) 0.74
0.45 106 (49–207) 104 (54–203) 0.57
INR = international normalized ratio; PT = prothrombin time.
Table 9. Secondary endpoints of the treatment groups.
Control rFVIIa p
Re-exploration 19 (9.3) 8 (3.4) 0.011
Renal failure 31 (14.9) 38 (16.2) 0.72
Dialysis 4 (1.9) 6 (2.5) 0.65
Pneumonia 11 (5.3) 17 (7.2) 0.4
Mediastinitis 6 (2.8) 9 (3.8) 0.58
Postop mechanical ventilation (d)a 11 (1–31) 8 (1–27) 0.06
CSICU stay (d)a 15 (1–41) 13 (1–36) 0.7
Hospital stay (d)a 41 (8–79) 38 (6–69) 0.8
30 mortality 5 (2.4) 5 (2.1) 0.84
Mortality at discharge 14 (6.7) 17 (7.2) 0.83
Data are presented as n (%) or median (range). (d)a Days.
CSICU = Cardiac Surgical Intensive Care Unit; Postop = postoperation.
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they were not significant compared with the other
group. No statistical significant difference was
noticed between the two groups regarding new
onset renal failure, dialysis requirement, pneumo-
nia, mediastinitis, CSICU, hospital length of stay,
survival at 30-days postoperatively, and survival
at discharge (Table 9).Discussion
We observed a significant decrease in the chest
tube bleeding, in the number of blood products
units transfused, and a nonsignificant higher inci-
dence of TAE among patients who received rFVIIa
compared with the patients who received only
conventional treatment.
Four hundred and eighty three (9.9%) of our
patients had postoperative bleeding, which is a
relatively high percentage compared with other
centers; however, this can be explained by the
type of our patients (with a high European System
for Cardiac Operative Risk Evaluation II score
ranging between 7 and 9, 50% were a redo, 15%
had emergency surgery, and 30% had preopera-
tive anticoagulation).
Although originally conceived as a treatment for
hemorrhage in hemophiliacs, this report suggests
that rFVIIa may be of benefit when given to car-
diac surgery patients who develop severe refrac-
tory blood loss. There is a clinical sentiment that
rFVIIa decreases bleeding. Several studies,
reviews, and meta-analysis have reported the role
of rFVIIa in controlling bleeding postcardiac sur-
gery [5–10,14–30].
The bleeding in the two treatment groups was
comparable in the first hours after admission to
CSICU, and then with the start of rFVIIa adminis-
tration (around 3 hours after admission) there was
a statistically significant drop in the bleeding from
the rFVIIa group which continued until the
bleeding in the other group was almost controlledafter 9 hours from admission. Also there was a
nonsignificant difference in the number of blood
product units transfused in the operating room
and in the first 3 hours in CSICU (before the
administration of rFVIIa). Taken together, this
decrease in chest tube bleeding can be clearly
attributed to the direct effect of rFVIIa.
In 2011, The Society of Thoracic Surgeons and
the Society of Cardiovascular Anesthesiologists
updated the Blood Conservation Clinical Practice
Guidelines stating that: use of rFVIIa concentrate
may be considered for the management of intract-
able nonsurgical bleeding that is unresponsive to
routine hemostatic therapy after cardiac proce-
dures using CPB Class IIb [31].
Although rFVIIa is being increasingly used, only
two randomized controlled trials examined its use
in cardiac surgery in adults: Gill et al. [14] in a ran-
domized placebo controlled trial showed that sig-
nificantly fewer patients in the FVIIa group
underwent a reoperation as a result of bleeding
or required allogenic transfusion. Also, there were
more critical serious adverse events in the FVIIa
group, although not statistically significant. For
the first time, a hemostatic agent has the possibil-
ity of being an effective alternative to allogeneic
transfusion in cardiac surgery patients with
uncontrolled postoperative bleeding. Disprose
et al. [6] showed in another pilot study that rFVIIa
significantly reduces the need for allogeneic trans-
fusion in complex noncoronary cardiac surgery
without causing adverse events. However, when
the results were analyzed by intention to treat,
the results were negative.
Karkouti et al. [15] published the largest study
analyzing the effect of rFVIIa to control refractory
bleeding after cardiac surgery. The study com-
pared 114 patients treated with rFVIIa versus 541
patients not treated with rFVIIa. The results
confirmed that rFVIIa significantly reduces the
hemorrhage and the transfusion requirements
without causing adverse effects; furthermore,
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UNCONTROLLED BLEEDING POSTCARDIAC SURGERYemphasizing that early treatment is associated
with better clinical progress.
However, many retrospective data analyses and
systemic reviews [32–40] concluded that the use of
rFVIIa as a rescue therapy has met with mixed
results. Although showing an overall benefit for
the application of rFVIIa, serious inherent publi-
cation bias associated with these reports does
not support its use, at least when employed pro-
phylactically. Also it did not show any effect on
mortality and may substantially increase the risk
for thromboembolic events.
In our report, TAEs were not significantly higher
in the FVIIa group compared with the control
group (5.5% vs. 2.4%, p = 0.27). Around 25% of
patients in both groups had preoperative TAE
(CVA, MI, or PE). This makes them a higher risk.
In addition, preoperative carotid duplex is not a
routine preoperative investigation, which if done
could have identified at-risk patients.
The main complication associated with rFVIIa is
thrombosis. In a systematic review [39] that
focused on the efficacy and safety of rFVIIa, the
incidence rate of thrombosis was 1–2%. Dunkley
et al. [41] reported an associated thromboembolic
rate in 4% of patients. Cardiac surgery patients
represent high-risk categories for systemic or
localized thrombosis after rFVIIa. The incidence
of TAEs in our study is comparable to others
[42]. Our patients had a relatively long CPB time
which can cause a more severe abnormality of
coagulation causing postoperative bleeding asso-
ciated with disseminated intravascular coagula-
tion and thrombosis when rFVIIa is used.
By contrast, Levi et al. [40] found an increased
risk of arterial thromboembolic events among
patients who received off-label rFVIIa as com-
pared with patients who received placebo for
bleeding episodes. Analysis of the rates of arterial
thromboembolism events according to the type of
bleeding showed that these rates were not signif-
icantly higher in cardiac surgery bleeding, possi-
bly because of the lower number of patients
included.
Zatta et al. [43] found that the overall unadjusted
thromboembolic adverse events rate was 10.9%,
with 48% of all TAEs occurring in cardiac surgery
patients. The majority of TAEs were arterial
(6.3%). They stated that in the absence of a suit-
able control group, it is difficult to draw any
meaningful conclusions on the overall rate of
TAEs reported to the registry.
In a case–control study using Australian and
New Zealand Hemostasis Registry patients and a
comparable group of patients from theAustralasian Society for Cardiac and Thoracic
Surgeons database, Mitra et al. [44] found no
increase in stroke or MI associated with the use
of rFVIIa.
Our results showed a significant improvement
in most of the coagulation parameters when mea-
sured 4 hours after admission to CSICU in the
rFVIIa group compared with the control group.
Fibrinogen showed an increase which was
insignificantly different between the two study
groups. This could be explained by the signifi-
cantly excessive transfusion of fresh frozen
plasma and cryoprecipitate in conventional treat-
ment group compared to rFVIIa group which
increased the fibrinogen level in this group more
than the rFVIIa group.
Our results show that eight patients needed re-
exploration after rFVIIa administration compared
with 19 patients in the control group, p = 0.011.
This relatively low incidence of re-exploration in
the FVIIa group can be explained—in addition to
the role of rFVIIa—by: (1) exclusion of surgical
causes of bleeding was worked out many times
before the administration of the drug; (2) rFVIIa
efficacy has been studied predominantly after
the patients had already received significant vol-
umes of blood products and antifibrinolytics
(tranexemic acid and desmopressin) prior to treat-
ment [25]. However, it has rarely been studied in
isolation.
Uber et al. [20] concluded that rFVII administra-
tion in the ICU appears comparable with reopera-
tion for refractory bleeding after complex
cardiovascular surgical procedures and might rep-
resent an alternative to reoperation in selected
patients.
Von Heymann et al. [7] found that the survival
rates after 6 months were similar in his study
groups which can be related to the delay in the
decision to using rFVIIa and to the fact that
patients had worsened. An important contribution
of his study [7] is the new concept of the ‘‘ideal’’
time in which rFVIIa should be used. Previous
studies had considered that rFVIIa as the last ther-
apeutic alternative to be used when other
resources had failed. The median time from leav-
ing the operating room until the administration of
rFVIIa in our patient groups was almost 3 hours,
including the time needed for preparation of the
drug by the pharmacy which is around
30 minutes.
The limitations of our study can be summarized
into the following. Firstly, being a retrospective
study, most findings should be viewed as associa-
tive rather than causative, and may be affected by
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plate for larger prospective evaluations of this
agent. Secondly, the number of bleeding patients
who received rFVIIa in our study was large
(53.1% of the whole patient population). This can
be explained by many factors: the whole cost for
all medical procedures is free to the patient once
he is eligible to be treated in this institution, so
making the decision is easier and there are no
financial consequences to the patients or to the
prescribing physician. Thirdly, the wide range of
rFVIIa dose used in our CSICU may be due to
the considerable heterogeneity among the
patients; baseline risk, surgical complexity, condi-
tion at time of rFVIIa therapy (e.g., amount and
rate of blood loss, hemodynamic status, organ
compromise). The decision to give rFVIIa involved
mostly the surgeon and the intensivist, but did not
involve the clinical pharmacist or the hematolo-
gist. The easy access to order the medication is
also another factor as the attending intensivist
and/or the surgeon alone is eligible to prescribe
the medication according to hospital policies.
Fourthly, although treatment with rFVIIa was
guided by a firm institutional clinical protocol that
involved correction of coagulation, pH, tempera-
ture, and ionized calcium, a point of care system
involving the thromboelastography would have
allowed a more accurate evaluation of the overall
clotting process and which blood product and/or
hemostatic agents, such as rFVIIa, would be
needed [45]. Recently, we have introduced throm-
boelastography in our CSICU. However, the train-
ing is still in evolution on the view of the
inconclusive results that we get sometimes. The
time needed to order and prepare the specific
blood product after the interpretation of the
thromboelastogram results is still long (at least
30 minutes) which makes the application of these
results to the protocol for the management of a
bleeding patient more difficult.
Nevertheless, to our knowledge, this is the lar-
gest study including a continuous series of
patients treated at a single institution according
to standardized clinical protocol that study the
efficacy and safety of rFVIIa in post cardiac surgi-
cal bleeding.Conclusion
FVIIa can be effective in controlling intractable
postoperative cardiac surgical bleeding and
reducing blood products transfused and re-
exploration rate; however, with nonsignificant
higher TEA events and no morbidity or survivalbenefit. Being an expensive medication, applica-
tion of a point-of-care protocol will help to better
choose the patients that will benefit FVIIa and
reduce the cost. Further prospective randomized
studies are needed to confirm these findings.Acknowledgments
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